| __timestamp | Ascendis Pharma A/S | United Therapeutics Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 381287000 |
| Thursday, January 1, 2015 | 9415000 | 452612000 |
| Friday, January 1, 2016 | 11504000 | 316800000 |
| Sunday, January 1, 2017 | 13482000 | 330100000 |
| Monday, January 1, 2018 | 25057000 | 265800000 |
| Tuesday, January 1, 2019 | 48473000 | 336200000 |
| Wednesday, January 1, 2020 | 76669000 | 423900000 |
| Friday, January 1, 2021 | 160180000 | 467000000 |
| Saturday, January 1, 2022 | 221227000 | 487000000 |
| Sunday, January 1, 2023 | 264410000 | 477100000 |
| Monday, January 1, 2024 | 284545000 |
Cracking the code
In the competitive landscape of biopharmaceuticals, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of United Therapeutics Corporation and Ascendis Pharma A/S from 2014 to 2023. Over this period, United Therapeutics consistently maintained higher SG&A expenses, peaking at approximately 487 million in 2022, reflecting a strategic investment in operational growth. In contrast, Ascendis Pharma A/S exhibited a remarkable upward trajectory, with expenses surging by over 4000% from 2014 to 2023, reaching around 264 million. This growth underscores Ascendis's aggressive expansion strategy. The data highlights the contrasting approaches of these companies in managing operational costs, offering insights into their strategic priorities. As the biopharma sector evolves, understanding these financial dynamics is key to predicting future industry trends.
Amgen Inc. or Ascendis Pharma A/S: Who Manages SG&A Costs Better?
Takeda Pharmaceutical Company Limited vs Ascendis Pharma A/S: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Alnylam Pharmaceuticals, Inc. or Ascendis Pharma A/S
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: SG&A Expense Trends
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Verona Pharma plc
United Therapeutics Corporation vs Ultragenyx Pharmaceutical Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for United Therapeutics Corporation and Alkermes plc
Selling, General, and Administrative Costs: United Therapeutics Corporation vs Geron Corporation
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Veracyte, Inc.
Breaking Down SG&A Expenses: Ascendis Pharma A/S vs Soleno Therapeutics, Inc.
Ascendis Pharma A/S or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and Travere Therapeutics, Inc.